It is probably time to be bullish as an investor. But remember two things. One: Valuations are still not cheap. Two: Because it is over and...

A gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...

As the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...

As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...

Novartis India has launched Pluvicto, the nation's first approved radioligand therapy for eligible prostate cancer patients. This precision...

India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...

There are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...

India's drug price regulator has increased the ceiling prices of cancer drugs cisplatin and carboplatin by 50% to tackle shortages caused b...

With an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The com...

Precision oncology startup 4baseCare has raised Rs 128 crore. This funding will expand its genomics labs globally and scale its AI platform...

India's government is taking emergency steps to ensure cancer patients get vital drugs. Cisplatin and carboplatin, crucial chemotherapy age...

British pharmaceutical giant GSK has announced a massive $10.6 billion deal to acquire Nuvalent. This Boston-based company specializes in c...

India continues its strong support for Afghanistan, reaffirms MEA. The nation is focused on peace, stability, and development. This include...

Cancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues a...

As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...

A 61-year-old woman endured eight months of severe pain, initially treated for acidity. Doctors eventually found a rare paraesophageal hiat...

The study, which followed patients for over five years, found that those ⁠who received ⁠the regimen were nine times more likely to have lit...